Her2+ Non Small Cell Lung Cancer Market | Size, Share, Growth

Her2+ Non Small Cell Lung Cancer Market Research Report - Size, Share, Growth, and Trend Analysis | Forecast (2025 - 2030)

Published: 2025 - March

Report Code: VMR-18251

Region: Global

Request Sample

Customization

Ask an Expert

Enquire Enquire Before Buying

Her2+ Non Small Cell Lung Cancer Market (2025-2030)

The HER2+ Non-Small Cell Lung Cancer (NSCLC) market focuses on a subset of NSCLC patients characterized by HER2 (Human Epidermal Growth Factor Receptor 2) overexpression or mutations, representing a unique and aggressive molecular profile. This niche but growing segment has become a critical area for targeted therapies, leveraging advancements in precision oncology to improve survival outcomes. HER2+ NSCLC requires specialized treatment strategies distinct from other lung cancer types, presenting significant opportunities for pharmaceutical innovation.

Disruptive Impact and Opportunities:

The market is experiencing a wave of disruptive transformation with cutting-edge therapies and diagnostics, capitalizing on the unmet clinical need. Advanced therapies like HER2-directed antibody-drug conjugates and small-molecule inhibitors are redefining treatment paradigms. Improved biomarker testing technologies facilitate rapid and accurate HER2 mutation identification, streamlining patient selection. The emphasis on precision-targeted therapies minimizes off-target effects, offering better safety profiles compared to conventional treatments. Rising incidence of HER2+ NSCLC, coupled with expanding applications of approved therapies, underscores the vast growth potential of this market.

Emerging Drugs:

DZD9008
Mobocertinib (TAK-788)

Marketed Drugs:

Pyrotinib

Key Companies:

Spectrum Pharmaceuticals
AstraZeneca
Daiichi Sankyo
Jiangsu HengRui Medicine
Dizal Pharmaceuticals
Takeda Pharmaceuticals

Market Segmentation:

By Type

Therapeutic Class
- Monoclonal Antibodies
- Antibody-Drug Conjugates (ADCs)
- Tyrosine Kinase Inhibitors (TKIs)
- Biosimilars
Line of Therapy
- First-Line Treatment
- Second-Line Treatment
- Subsequent Lines

By Administration Type

Route of Administration
- Intravenous (IV)
- Oral
- Subcutaneous
Frequency of Administration
- Single Dose
- Multiple Doses (Weekly/Biweekly/Monthly)

What’s in It for You?

Comprehensive insights into market dynamics, competitive landscape, and growth drivers.
Detailed profiles of emerging therapies and their potential market impact.
Key trends in R&D pipelines and regulatory pathways.
Data-driven forecasts to support strategic planning and investment decisions.
Competitive intelligence to identify partnership and acquisition opportunities.

Her2+ Non Small Cell Lung Cancer Market - Executive Summary
1. Introduction
2. Objectives
3. Key Findings
  1. Market Size 2025 & 2030: By Key Country (10MM)
  2. Global Market Size 2025 & 2030: By Key Segment
  3. Key Investments & Startup Analysis
4. Research Methodology
Understanding the Disease
1. Disease Overview
2. Classification
3. Signs and Symptoms
4. Risk Factors
5. Causes
6. Disease Biology & Digital Innovations
7. Stages & Staging System
8. Diagnostic Algorithm
9. Current Treatment Practices & Algorithm
10. Current Standard of Care and Treatment Gaps
11. Patient Demographics and Treatment Pathways
Guidelines
Unmet Needs
Epidemiology and Patient Population
1. Epidemiology Key Findings
2. Assumptions and Rationale: 10MM
3. Epidemiology Scenario: 10MM
4. U.S. Epidemiology Scenario
5. EU-5 Epidemiology
  1. U.K. Epidemiology Scenario
  2. Germany Epidemiology Scenario
  3. France Epidemiology Scenario
  4. Italy Epidemiology Scenario
  5. Spain Epidemiology Scenario
6. Japan Epidemiology Scenario
7. China Epidemiology Scenario
8. Australia Epidemiology Scenario
9. India Epidemiology Scenario
Real-world Data & Real-world Evidence
Drug Development Landscape
1. Existing Key Drug Candidate Profiles/ Marketed Therapies
2. Competitive Analysis and Differentiation
3. Overview of Similar/Competing Drugs in Clinical Trials
4. Future Trends and Emerging Drugs
Regulatory Strategy and Potential Challenges
1. Regulatory Pathways in Key Markets
2. Anticipated Regulatory Hurdles and Mitigation Strategies
3. Case Studies in Oncology Drug Regulation
4. Impact of Potential Changes to Regulatory Framework
Commercial Landscape
1. Market Size & Growth Rates
2. Key Approvals & Anticipated Loss of Exclusivity
3. PESTLE & Porter’s Five Forces Analysis
4. Market Shares, Positioning/Ranking
5. Market Drivers
6. Identification of Threats
7. Digital Evolution in Commercialization
Market Segmentation
Pricing, Reimbursement, and Access
1. Competitive Pricing Analysis
2. Reimbursement Landscape and Challenges
3. Strategies for Market Access and Equity
4. Patient Spending/Expenditure Analysis
Future Trends, Disruptions, and Opportunities
1. Analysis of Emerging Trends
2. Technological Impact
3. Impact of Potential Market Disruptors
4. Opportunities for Future Development and Expansion
5. Considerations for Investment Opportunities
Global Market Dynamics
1. Regional Regulatory Disparities
2. Cross-Border Partnership Strategies
3. Global Supply Chain Dynamics
4. Case Studies: Success and Failure in Global Markets
5. Strategies for Global Expansion and Localization
Company Profiles

Download Sample

Full Name *

Job Title *

Company *

Email *

Phone *

Country *

Message

↻

The field with (*) is required.

Choose License Type

Excel Data Pack

2500

Single User

4250

Multi User

5250

Corporate User

6900